<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602923</url>
  </required_header>
  <id_info>
    <org_study_id>20.240</org_study_id>
    <nct_id>NCT04602923</nct_id>
  </id_info>
  <brief_title>Keratometric Change After XEN, Trabeculectomy and Tube Shunts</brief_title>
  <acronym>Topo-XEN</acronym>
  <official_title>Comparison of Keratometric Change After Xen Gel Stent Implantation, Trabeculectomy, and Tube Shunts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to assess the severity of postoperative corneal astigmatism&#xD;
      induced by implantation of the XEN Gel Stent compared to that induced by traditional&#xD;
      filtering surgery (trabeculectomy and GDDs). Corneal astigmatism can be assessed using&#xD;
      corneal topography, a non-invasive tool which provides an accurate estimate of corneal&#xD;
      curvature in all meridians. To the best of our knowledge, no study has yet attempted to&#xD;
      quantify the amount of astigmatism induced by the XEN Gel Stent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following glaucoma surgery, patients often experience decreased visual acuity (VA) which can&#xD;
      partly be explained by induced changes to the optical properties of the cornea. Corneal&#xD;
      astigmatism can be assessed using corneal topography, a non-invasive tool which provides an&#xD;
      accurate estimate of corneal curvature in all meridians. Obtained keratometric measures&#xD;
      (termed K values) can allow clinicians to quantify the amount of astigmatism before and after&#xD;
      surgical intervention.&#xD;
&#xD;
      Multiple studies have been previously published to evaluate induced postoperative astigmatism&#xD;
      after trabeculectomy. However, only two studies have characterized the impact of GDDs on&#xD;
      keratometric values. To the best of our knowledge, no study has yet attempted to quantify the&#xD;
      amount of astigmatism induced by the XEN Gel Stent.&#xD;
&#xD;
      Assessing the impact of the XEN implant on corneal astigmatism is important to better&#xD;
      characterize the expected course of postoperative visual rehabilitation, the impact of novel&#xD;
      glaucoma devices on corneal properties and the predictability of refractive outcomes after&#xD;
      XEN implantation. Compared to traditional filtering surgery, the XEN Gel Stent is inserted&#xD;
      without opening the conjunctiva and is implanted further from the corneal limbus (5 mm).&#xD;
      These factors may allow for a reduced amount of surgically induced corneal astigmatism.&#xD;
&#xD;
      We hypothesize that the XEN Gel Stent implantation induces less corneal astigmatism compared&#xD;
      to traditional filtering surgery, such as the trabeculectomy and GDDs (BGI or AGV).&#xD;
&#xD;
      The main goal of this prospective interventional comparative study is to assess the severity&#xD;
      of postoperative corneal astigmatism induced by implantation of the XEN Gel Stent compared to&#xD;
      that induced by traditional filtering surgery (trabeculectomy and GDDs).&#xD;
&#xD;
      Secondary objectives are evaluation of visual acuity recovery as well as IOP reduction and&#xD;
      other parameters between groups.&#xD;
&#xD;
      Glaucoma surgery (XEN Gel Stent, trabeculectomy or GDD implantation) will be performed by the&#xD;
      ophthalmologists in charge of the study according to standard procedures. For each patient,&#xD;
      the most appropriate type of glaucoma surgery will be recommended by the ophthalmologist&#xD;
      regardless of patients' participation in the study, as dictated by the specific nature of&#xD;
      their glaucoma and following current standards of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>3 groups will be compared:&#xD;
Group 1: 30 participants suffering from glaucoma who are candidates for XEN Gel Stent implantation&#xD;
Group 2: 30 participants suffering from glaucoma who are candidates for trabeculectomy&#xD;
Group 3: 30 participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Keratometric values (OPD-Scan)</measure>
    <time_frame>Baseline, 2 months, 6 months, 12 months</time_frame>
    <description>Change in simulated keratometric (K) values obtained by OPD-Scan between the indicated timepoints.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Keratometric values (Pentacam)</measure>
    <time_frame>Baseline, 2 months, 6 months, 12 months</time_frame>
    <description>Change in simulated keratometric (K) values obtained by Pentacam between the indicated timepoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity change</measure>
    <time_frame>Baseline, 2 months, 6 months, 12 months</time_frame>
    <description>Evaluation of visual acuity change, measured using the Snellen chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure change</measure>
    <time_frame>Baseline, 2 months, 6 months, 12 months</time_frame>
    <description>Evaluation of intraocular pressure control, measured using gold standard Goldmann applanation tonometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field change change</measure>
    <time_frame>Baseline, 2 months, 6 months, 12 months</time_frame>
    <description>Evaluation of visual field change. Visual field change will be calculated using the mean deviation (MD) values and pattern standard deviation (PSD) values measured using automated Humphrey 24-2 perimetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal nerve fiber layer thickness change</measure>
    <time_frame>Baseline, 2 months, 6 months, 12 months</time_frame>
    <description>Evaluation of retinal nerve fiber layer (RNFL) thickness change (µm), using the average RNFL thickness values measured using Spectral Domain Optical Coherence Tomography (SD-OCT). The change in thickness (µm) will be calculated between the time points described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganglion cell layer thickness change</measure>
    <time_frame>Baseline, 2 months, 6 months, 12 months</time_frame>
    <description>Evaluation of ganglion cell layer (GCL+) thickness. This GCL+ thickness is measured using the values for the average ganglion cell layer and inner plexiform layer thickness of the retina (value called &quot;Average GCL + IPL thickness&quot;) obtained by Spectral Domain Optical Coherence Tomography (SD-OCT). The change in thickness (µm) will be calculated between the time points described.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma, Angle-Closure</condition>
  <condition>Glaucoma Secondary</condition>
  <condition>Glaucoma Eye</condition>
  <arm_group>
    <arm_group_label>XEN Gel Stent implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants suffering from glaucoma who are candidates for XEN Gel Stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants suffering from glaucoma who are candidates for trabeculectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDD implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants suffering from glaucoma who are candidates for GDD implantation (BGI or AGV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Corneal topography: OPD-Scan</intervention_name>
    <description>Corneal topography photography, taken by specular reflection (OPD-Scan) by measuring corneal curvature, thickness and topography.</description>
    <arm_group_label>GDD implantation</arm_group_label>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_label>XEN Gel Stent implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Corneal topography: Pentacam</intervention_name>
    <description>Corneal topography photography, taken by Scheimpflug imaging (Pentacam) by measuring corneal curvature, thickness and topography.</description>
    <arm_group_label>GDD implantation</arm_group_label>
    <arm_group_label>Trabeculectomy</arm_group_label>
    <arm_group_label>XEN Gel Stent implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eyes with an IOP above target and/or progressing on maximally tolerated medical&#xD;
             therapy;&#xD;
&#xD;
          -  Patients aged 18 years or older;&#xD;
&#xD;
          -  Ability to provide informed consent;&#xD;
&#xD;
          -  Ability to be followed for the entire duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients less than 18 years old;&#xD;
&#xD;
          -  Inability to provide informed consent;&#xD;
&#xD;
          -  Inability to be followed for the entire duration of the study;&#xD;
&#xD;
          -  Patients undergoing surgery combined with cataract extraction;&#xD;
&#xD;
          -  Presence of severe dry eye disease;&#xD;
&#xD;
          -  Presence of ocular comorbidities other than glaucoma, such as corneal or retinal&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges Durr, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Catherine Tessier, MSc</last_name>
    <phone>1-514-890-8000</phone>
    <phone_ext>11550</phone_ext>
    <email>marie-catherine.tessier.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique Geoffrion, BSc</last_name>
    <phone>1-514-890-8000</phone>
    <phone_ext>11550</phone_ext>
    <email>dominique.geoffrion@mail.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Catherine Tessier, MSc</last_name>
      <phone>1-514-890-8000</phone>
      <phone_ext>11550</phone_ext>
      <email>marie-catherine.tessier.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Georges Durr, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Younes Agoumi, MD, FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006 Mar;90(3):262-7.</citation>
    <PMID>16488940</PMID>
  </reference>
  <reference>
    <citation>Banitt M. Evaluation and management of glaucoma after keratoprosthesis. Curr Opin Ophthalmol. 2011 Mar;22(2):133-6. doi: 10.1097/ICU.0b013e328343723d. Review.</citation>
    <PMID>21191292</PMID>
  </reference>
  <reference>
    <citation>Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012 Mar;23(2):96-104. doi: 10.1097/ICU.0b013e32834ff1e7. Review.</citation>
    <PMID>22249233</PMID>
  </reference>
  <reference>
    <citation>Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLoS One. 2017 Aug 29;12(8):e0183142. doi: 10.1371/journal.pone.0183142. eCollection 2017. Review.</citation>
    <PMID>28850575</PMID>
  </reference>
  <reference>
    <citation>Chatzara A, Chronopoulou I, Theodossiadis G, Theodossiadis P, Chatziralli I. XEN Implant for Glaucoma Treatment: A Review of the Literature. Semin Ophthalmol. 2019;34(2):93-97. doi: 10.1080/08820538.2019.1581820. Epub 2019 Feb 21. Review.</citation>
    <PMID>30789072</PMID>
  </reference>
  <reference>
    <citation>Chan HHL, Kong YXG. Glaucoma surgery and induced astigmatism: a systematic review. Eye Vis (Lond). 2017 Nov 17;4:27. doi: 10.1186/s40662-017-0090-x. eCollection 2017. Review.</citation>
    <PMID>29177182</PMID>
  </reference>
  <reference>
    <citation>Pakravan M, Alvani A, Esfandiari H, Ghahari E, Yaseri M. Post-trabeculectomy ocular biometric changes. Clin Exp Optom. 2017 Mar;100(2):128-132. doi: 10.1111/cxo.12477. Epub 2016 Sep 29. Review.</citation>
    <PMID>27686794</PMID>
  </reference>
  <reference>
    <citation>Koivusalo R, Välimäki J. Effect of glaucoma drainage implant surgery on corneal topography: a prospective study. Acta Ophthalmol. 2020 May;98(3):305-309. doi: 10.1111/aos.14247. Epub 2019 Sep 8.</citation>
    <PMID>31495070</PMID>
  </reference>
  <reference>
    <citation>Miraftabi A, Lotfi M, Nilforushan N, Abdolalizadeh P, Jafari S. Ocular biometric changes after Ahmed glaucoma valve implantation. Eur J Ophthalmol. 2021 Jan;31(1):120-124. doi: 10.1177/1120672119889528. Epub 2019 Nov 21.</citation>
    <PMID>31752527</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma drainage devices</keyword>
  <keyword>Xen Gel Stent</keyword>
  <keyword>Baerveldt glaucoma implant</keyword>
  <keyword>Ahmed glaucoma implant</keyword>
  <keyword>Trabeculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

